KUALA LUMPUR, NTS Ventures (NTS) and International Health Management Associates Inc (IHMA) have announced a collaborative agreement to provide the pharmaceutical industry with a brand-new antifungal resistance surveillance programme known as STAR.
The Susceptibility Trends in Antifungal Resistance (STAR) programme is heavily supported through affiliations with key opinion leader laboratories worldwide.
As antifungal resistance rises and epidemiology changes, STAR will intimately monitor fluctuations and trends in antifungal resistance and epidemiology over time.
It will be an excellent tool to serve authorities, biotechnology and pharmaceutical companies in the relentless fight against antifungal drug resistance.
The clinical isolates prospectively collected via STAR will include all major yeasts (including the emerging pathogen, Candida auris) and filamentous fungi, such as Aspergillus spp. as well as the rarer and highly invasive mold species such as Mucor spp., Rhizopus spp., among others.
The development of new antifungal agents is increasing. Consequently, STAR will support these drugs to ensure the fight against antifungal resistance will be more efficient and gain precious time in reducing and eventually eliminating new resistance.
The agreement will allow all pharmaceutical and biotech companies access to the STAR programme in a cost and time-effective manner.
Source: BERNAMA (News Agency)